The clinical trial ecosystem faces mounting challenges, including fragmented data sources, escalating costs, and increasingly intricate trial designs, complicating patient identification, protocol, and site selection. These hurdles often delay the delivery of life-saving therapies and invariably drive-up development costs.
In this CRA Insights, Ayushman Ghosh and Alex Dreisbach detail how integrating structured data from prior trials and regulatory guidance in addition to real-world evidence (RWE), offer transformative solutions to these issues, presenting an opportunity to enhance efficiency, delivery, and precision in clinical trials.
Read more about unlocking the power of RWE and structured data here
